Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m

15:33 EDT 5 May 2018 | SCRIP

April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent...

More From BioPortfolio on "Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m"